6 results about "Release modulator" patented technology

The present application belongs to the field of pharmaceutical preparations, and particularly relates to a sustained-release analgesic pharmaceutical composition, a method for preparing same, and use thereof. The pharmaceutical composition of the present application comprises a drug, a delivery carrier, and a release regulator. The drug is selected from at least one of a local anesthetic and a non-steroidal anti-inflammatory drug. The release regulator is selected from a phospholipid compound. The delivery carrier is selected from a saccharide and an esterified form thereof. According to the present application, the coaction of the phospholipid compound and the delivery carrier can increase the plasma drug concentration upon the initial release in vivo, reduce the time to peak, enhance the analgesic effect in the early stage after a surgery, and ensure the long-term release of the drug, thus effectively relieving the postoperative pain, reducing the administration frequency, and promoting skin wound healing. The use of a specific solubilizer provides good stability for the drug and prevents precipitation. The composition can be administered through the wound, making it easy to use.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a sustained-release analgesic pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a drug, a delivery carrier and a release regulator, the medicine is selected from at least one of local anesthetics and non-steroidal anti-inflammatory drugs; the release regulator is selected from phospholipid compounds; the delivery carrier is selected from saccharides and esters thereof. According to the invention, the phospholipid compound is adopted as the release regulator, and the phospholipid compound and the delivery carrier act together to increase the initial release blood concentration of the drug in vivo, shorten the peak time of the blood concentration, enhance the analgesic drug effect at the initial stage of the operation, maintain the long-acting release of the drug, effectively relieve the postoperative pain, reduce the administration frequency, and meanwhile, improve the bioavailability of the drug. The effects of promoting skin wound healing and repairing are also achieved; a specific type of solubilizer is adopted, so that the medicine has good stability and is not easy to separate out; in addition, the pharmaceutical composition disclosed by the invention can be directly administrated through a wound and is convenient to use.

The invention relates to the technical field of drug sustained-release microspheres, and particularly provides a dalotamide sustained-release microsphere which is of a structure composed of an inner layer and an outer layer, and the inner layer is coated with the outer layer; the inner layer is prepared from the following raw material components: first PLGA and dalotamide; the outer layer is prepared from the following raw material components: second PLGA, dalotamide dispersed particles and a release regulator; the dalotamide dispersed particles are prepared from the dalotamide and Soluplus; the release regulator is selected from a hydrophilic substance and / or a pore-foaming agent. According to the microspheres disclosed by the invention, the programmed release effect of'early-stage quick release-medium-stage stable release-long-term slow release 'of the dalotamide can be realized, and the stability of the dalotamide is good.

An oral drug delivery device for the controlled delivery of a lipophilic drug, the device comprising a lipophilic drug emulsified in a film-forming hydrophilic polymer, a release modifier, and an emulsifier, the device being incorporated into or formed as an orally administrable unit dosage form, wherein upon ingestion of the unit dosage form and contact with the gastric and / or intestinal media, the release modifier forms a viscous gel that gradually erodes as it travels through the stomach and intestinal tract, releasing the emulsified drug into the surrounding environment at a controlled rate.

The invention discloses a lyotropic liquid crystal long-acting injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation consists of a raw material medicine, a lipid material, an organic solvent and a release regulator, and hexagonal phase liquid crystal gel can be spontaneously formed after injection so as to realize long-acting slow release. The preparation can be prepared by stirring and mixing at room temperature, and has the advantage of simple and convenient preparation process. Experiments show that the effective blood concentration in the body can be maintained for more than 14 days after single hypodermic injection, the half-life period of the medicine is prolonged to 187 hours from about 66 hours of oral administration, and the burst release phenomenon is avoided. The invention effectively solves the clinical pain points of frequent administration, large blood concentration fluctuation, poor patient compliance and the like of the existing oral preparation of the hydrobromic acid vortioxetine.

This invention belongs to the field of pharmaceutical technology, specifically relating to an injectable sustained-release composition, its preparation method, and its application. Through extensive research, this invention unexpectedly discovered that adding specific release modifiers can significantly slow down the early release rate of drugs. Furthermore, there is a synergistic effect between specific release modifiers and specific structure modifiers, which can effectively improve the sustained-release performance of the composition and significantly reduce the coefficient of variation among individual animals.